Tregs found in ovarian cancer lesions suppress the immune response to tumor-associated antigens, which is achieved by the suppression of Interferon gamma (IFN-γ) and interleukin-2 (IL-2) secretion by the effector T cells. Here, IFNG is linked to neoplasm.